MedTrace Logo

Treatment of Bacterial Vaginosis Combined With Human Lactobacilli

NCT01245322 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2014-11-10

No results posted yet for this study

Summary

The primary objectives of this study were to characterize lactobacilli of human vaginal origin and to investigate if more extended antibiotic treatment against Bacterial Vaginosis, together with adjuvant lactobacilli treatment, could increase the cure rate and furthermore, to investigate factors that could influence relapse.

Conditions

  • Bacterial Vaginosis

Interventions

DRUG

lactobacilli

women were given a seven days course of daily 2% vaginal clindamycin cream (Dalacin vaginal cream 2%, Pfizer Norway Ltd) together with oral clindamycin 300 mg BID for 7 days (Dalacin 300 mg, Pfizer Norway Ltd). Oral clindamycin treatment was also given to the patient's sexual partner.

Sponsors & Collaborators

  • Karolinska University Hospital

    collaborator OTHER

  • Skaraborg Hospital

    lead OTHER_GOV

Principal Investigators

  • Per-Göran Larsson, professor · Skaraborg hospital and University College of Skövde, SE-541 85 Skövde, Sweden

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01245322 on ClinicalTrials.gov